6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2013.

Commission File Number ________________

Novogen Limited

(Translation of registrant’s name into English)

16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 Form 20-Fx Form 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes  o No x

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novogen Limited (Registrant)

(Signature) *

Andrew Bursill

Date 21 October 2013

* Print the name and title under the signature of the signing officer.

EX-99

NOVOGEN LIMITED

(ASX: NRT)

ASX RELEASE

21 October 2013

Purchase of Convertible Security

NovogentodayannouncedthatithasundertheConvertibleSecurities

Agreementreferredtoinitsannouncementof4July2013,issuedasecond

convertible  security  to  its  US  based  institutional  investor.    This  will  raise

another $1 million to fund Novogen’s continued drug development program.

The terms of the Convertible Securities Agreement remain unchanged.

Dr Graham Kelly, Novogen CEO said. “We recently announced the acquisition

ofaseconddrugtechnologyplatformknownasanti-tropomyosins.Thefunds

raisedthroughtheissuanceofthisconvertiblesecuritywillbeappliedtothe

development of that drug platform.”

About Novogen

Novogen Ltd is a public Australia biotechnology company whose shares trade

onboththeAustraliaStockExchange(symbol‘NRT’)andNASDAQ(symbol

‘NVGN’).ThecompanyisbasedinSydney,Australia,withanofficeinIthaca,

NY,USA.TheCompanyisfocusedonthedevelopmentofdrugstrategies

thatwilldeliverpersonalizedchemotherapybasedontheeffectiveelimination

of cancer stem cells and somatic cancer cells across a range of genotypes.

Yours truly,

Lionel Mateo

Company Secretary

NOVOGEN LTD – ACN 063 259 754

16-20 Edgeworth David Ave, Hornsby, NSW, 2077

P: +61 (0) 2 9476 0344 -  F: +61 (0) 2 9476 0388

www.novogen.com